Alzheimer's Disease: Clinical features, pathogenesis, and treatment

被引:8
|
作者
Rathmann, Kaye L. [1 ]
Conner, Christopher S. [1 ]
机构
[1] Univ Colorado, Sch Med, Rocky Mt Drug Consultant Ctr, Denver Gen Hosp, Denver, CO 80204 USA
关键词
Alzheimer's disease; presenile dementia; choline; lecithin; physostigmine; naloxone;
D O I
10.1345/aph.140065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alzheimer's disease is an insidious degenerative disease of the brain and is the leading cause of dementia in the U.S. Numerous etiologies have been postulated, including a large body of evidence suggesting a slow viral infection, possibly in genetically predisposed individuals, but this remains to be proven. Differential diagnosis is based primarily on exclusion of other treatable forms of dementia. Neurochemical studies suggest a cholinergic deficit; thus primary emphasis in treatment has been directed at enhancing cholinergic activity. Choline and lecithin supplementation generally has been ineffective. Results with physostigmine are encouraging and further studies with this drug prototype are needed. Physostigmine's clinical usefulness is limited, however, due to peripheral side effects and its short duration of action. Other pharmacological approaches, such as naloxone, neural metabolic enhancers, stimulants, and vasopressin analogs, have been investigated. The clinical features and pathology of the disease are reviewed.
引用
收藏
页码:1499 / 1504
页数:6
相关论文
共 50 条
  • [21] Pathogenesis of Alzheimer's disease
    Swerdlow, Russell H.
    CLINICAL INTERVENTIONS IN AGING, 2007, 2 (03) : 347 - 359
  • [22] Alzheimer's Disease-Related Psychosis: An Overview of Clinical Manifestations, Pathogenesis, and Current Treatment
    Benmelouka, Amira Y.
    Ouerdane, Yassamine
    Outani, Oumaima
    Alnasser, Yusra T.
    Alghamdi, Badrah S.
    Perveen, Asma
    Ashraf, Ghulam Md
    Ebada, Mahmoud Ahmed
    CURRENT ALZHEIMER RESEARCH, 2022, 19 (04) : 285 - 301
  • [23] Mitophagy pathways and Alzheimer's disease: From pathogenesis to treatment
    Pan, Xian-Ji
    Misrani, Afzal
    Tabassum, Sidra
    Yang, Li
    MITOCHONDRION, 2021, 59 : 37 - 47
  • [24] Role of Infection in the Pathogenesis of Alzheimer's Disease Implications for Treatment
    Holmes, Clive
    Cotterell, Darren
    CNS DRUGS, 2009, 23 (12) : 993 - 1002
  • [25] Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
    Kirsten L. Viola
    William L. Klein
    Acta Neuropathologica, 2015, 129 : 183 - 206
  • [26] Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease
    Khan, Sahil
    Barve, Kalyani H.
    Kumar, Maushmi S.
    CURRENT NEUROPHARMACOLOGY, 2020, 18 (11) : 1106 - 1125
  • [27] Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
    Viola, Kirsten L.
    Klein, William L.
    ACTA NEUROPATHOLOGICA, 2015, 129 (02) : 183 - 206
  • [28] Nerve growth factor in treatment and pathogenesis of Alzheimer's disease
    Williams, Brice J.
    Eriksdotter-Jonhagen, Maria
    Granholm, Ann-Charlotte
    PROGRESS IN NEUROBIOLOGY, 2006, 80 (03) : 114 - 128
  • [29] ALZHEIMERS-DISEASE - CLINICAL-FEATURES, PATHOGENESIS, AND TREATMENT
    RATHMANN, KL
    CONNER, CS
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (09): : 684 - 691
  • [30] Alzheimer's disease: Clinical treatment options
    Reichman, WE
    AMERICAN JOURNAL OF MANAGED CARE, 2000, 6 (22): : S1125 - S1138